Division of Cardiology, State University of Rio de Janeiro, Rio de Janeiro, Brazil.
Diabetol Metab Syndr. 2010 Jan 15;2:2. doi: 10.1186/1758-5996-2-2.
The prevalence of pre-diabetes is increasing worldwide and may start 7 to 10 years before the clinical diagnosis of diabetes. In this stage the presence and accumulation of risk factors is common and already implies an increase in cardiovascular risk. Likewise, the onset of cardiovascular diseases (CVD), mainly coronary artery disease (CAD), peripheral vascular disease and cerebrovascular disease can also take place, all of which account for high rates of morbidity and mortality worldwide. Considering pre-diabetes as a clinical entity, non-pharmacological and pharmacological treatments are indicated with drugs which have shown clinical benefits related to reduction in morbidity and mortality. However, there is still need for new long-term studies to assess the real benefits of several new therapeutical approaches, as well as its cost-effectiveness.
全球范围内，糖尿病前期的患病率正在不断增加，并且可能在临床诊断糖尿病前 7 至 10 年就已经出现。在这一阶段，各种风险因素已经显现并开始积聚，这意味着心血管风险已经增加。同样，心血管疾病（CVD）的发作，主要是冠状动脉疾病（CAD）、外周血管疾病和脑血管疾病，也可能随之发生，所有这些都导致了全球范围内高发病率和死亡率。鉴于糖尿病前期是一种临床实体，因此需要进行非药物和药物治疗，这些药物已经显示出与降低发病率和死亡率相关的临床获益。然而，仍需要新的长期研究来评估几种新的治疗方法的实际获益及其成本效益。
